India, March 26 -- The Ozempic craze is not yet over. Originally developed for type 2 diabetes, the drug that took celebrities and social media by storm for its weight loss effects now has a new competitor in the Indian market. Enter Eli Lilly, an American pharmaceutical company, which launched Mounjaro (tirzepatide) in India last week on March 20.

Mounjaro works by targeting two key hormones - GIP (Glucose-Dependent Insulinotropic Polypeptide), which enhances insulin release from the pancreas in response to food intake, and GLP-1 (glucagon-like peptide-1), which regulates blood sugar levels by stimulating insulin secretion and reducing glucagon release. This once-a-week injection has been approved by India's drug regulatory authority fo...